P Schoenfeld Asset Management LP Acquires Shares of 175,640 TESARO Inc (TSRO)

Share on StockTwits

P Schoenfeld Asset Management LP acquired a new stake in shares of TESARO Inc (NASDAQ:TSRO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 175,640 shares of the biopharmaceutical company’s stock, valued at approximately $13,041,000. TESARO makes up approximately 1.4% of P Schoenfeld Asset Management LP’s investment portfolio, making the stock its 16th biggest holding.

A number of other hedge funds also recently modified their holdings of the stock. Gateway Investment Advisers LLC boosted its position in TESARO by 0.9% during the fourth quarter. Gateway Investment Advisers LLC now owns 26,133 shares of the biopharmaceutical company’s stock valued at $1,940,000 after purchasing an additional 223 shares in the last quarter. Kistler Tiffany Companies LLC raised its stake in TESARO by 166.7% in the fourth quarter. Kistler Tiffany Companies LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 250 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in TESARO by 18.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,735 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 269 shares during the last quarter. Miracle Mile Advisors LLC raised its stake in TESARO by 4.0% in the fourth quarter. Miracle Mile Advisors LLC now owns 7,850 shares of the biopharmaceutical company’s stock valued at $583,000 after buying an additional 300 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in TESARO by 0.8% in the fourth quarter. Rhumbline Advisers now owns 39,173 shares of the biopharmaceutical company’s stock valued at $2,909,000 after buying an additional 315 shares during the last quarter.

A number of research firms have commented on TSRO. HC Wainwright cut TESARO from a “buy” rating to a “neutral” rating in a research note on Friday, December 7th. Barclays cut TESARO from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $48.00 to $75.00 in a research note on Sunday, December 9th. Robert W. Baird set a $75.00 price target on TESARO and gave the company a “hold” rating in a research note on Monday, December 3rd. Wedbush cut TESARO from an “outperform” rating to a “neutral” rating and increased their price target for the company from $60.00 to $75.00 in a research note on Tuesday, December 4th. Finally, Gabelli cut TESARO from a “buy” rating to a “hold” rating in a research note on Monday, December 3rd. Eighteen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. TESARO presently has a consensus rating of “Hold” and a consensus target price of $72.79.

Shares of NASDAQ:TSRO opened at $74.96 on Friday. TESARO Inc has a 52-week low of $23.41 and a 52-week high of $75.16. The stock has a market capitalization of $4.13 billion, a PE ratio of -8.17 and a beta of 0.38.

COPYRIGHT VIOLATION WARNING: “P Schoenfeld Asset Management LP Acquires Shares of 175,640 TESARO Inc (TSRO)” was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://weekherald.com/2019/03/17/p-schoenfeld-asset-management-lp-acquires-shares-of-175640-tesaro-inc-tsro.html.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Further Reading: Is a Roth IRA right for you?

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.